Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ILKN421H and Pembrolizumab in Advanced NSCLC
NCT07452224Phase 2Recruiting
- Sponsor
- iLeukon Therapeutics
- Start
- Jun 2026
- Primary completion
- Jun 2029
- Modality
- Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ILKN421H in non-small cell lung cancer (NSCLC) (4 arms), sponsored by iLeukon Therapeutics. Primary endpoints: Treatment-Related Adverse Events up to 3 years and Objective Response Rate up to 3 years. Started Jun 2026; status: recruiting.
02
Drugs
ILKN421H
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07452224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07452224.